Top Markets
#1 Status Status +19.39%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.43%
#3 GoPlus Security GoPlus Security +12.56%
#4 Fake World Assets Fake World Assets +10.48%
#5 DMT-NAT DMT-NAT +9.49%
#6 Ontology Gas Ontology Gas +9.19%
#7 Provenance Blockchain Provenance Blockchain +6.74%
#8 o1.exchange o1.exchange +6.72%
#9 Janction Janction +6.56%
#10 B3 (Base) B3 (Base) +5.41%
Coin of the day
Status Status
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Kineta, Inc. Kineta, Inc.

Kineta, Inc.

KA
Rangering i aksjer #34154
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing... Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Aksjekurs
$0.617
Sist synkronisert: 2024-10-14
Markedsverdi
$6.13M
Endring (1 dag)
0.49%
Endring (1 år)
0.00%
Land
US
Handel Kineta, Inc. (KA)

Kategori

Healthcare
Inntekter for Kineta, Inc. (KA)
Inntekter i Mar 2025 TTM: $4.34M
Ifølge de nyeste økonomiske rapportene til Kineta, Inc. er selskapets nåværende inntekter (TTM) $4.34M. I 2023 hadde selskapet inntekter på $5.44M en økning sammenlignet med inntektene i 2022, som var $1.95M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Kineta, Inc. fra 2015 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $4.34M 0.00%
2024 0.00 -100.00%
2023 $5.44M 178.65%
2022 $1.95M -78.52%
2021 $9.09M -13.32%
2020 $10.49M 109.76%
2019 $5.00M 76.06%
2018 $2.84M -46.83%
2017 $5.34M -36.30%
2016 $8.38M 94.43%
2015 $4.31M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 290,916.60%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 138,703.30%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 232,974.84%
BE